2-Pyridone Derivatives Inhibit Neutrophil Elastase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human neutrophil elastase (hNE) is a destructive enzyme implicated in various inflammatory diseases due to its uncontrolled proteolytic activity, leading to tissue destruction and imbalance with its endogenous inhibitor, α1-antitrypsin, which is not effectively addressed by existing therapies.
Innovation Solution
Development of novel 2-pyridone derivatives that act as inhibitors of human neutrophil elastase and homologous serine proteases, such as proteinase 3 and pancreatic elastase, to mitigate tissue destruction and inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to address the imbalance between hNE and α1-antitrypsin, then the protease-antiprotease balance may be partially improved, but the destructive proteolytic activity of hNE remains uncontrolled and tissue destruction continues
Solution Approach 1:
The patent introduces novel 2-pyridone derivatives as intermediary substances that directly inhibit hNE activity. These compounds act as mediators between the excessive protease and the tissue, preventing the destructive interaction without requiring restoration of the natural antiprotease balance. The inhibitors bind to the active site of hNE, blocking its proteolytic activity and thereby preventing tissue destruction.
Solution Approach 2:
The patent modifies the chemical structure of 2-pyridone derivatives with specific substituents (aromatic rings, heteroaromatic rings, alkyl groups) to optimize the inhibition parameters. By changing molecular parameters such as lipophilicity, hydrogen bonding capacity, and steric properties, the compounds achieve high-affinity binding to hNE with selective inhibition, thereby changing the kinetic parameters of the protease-antiprotease system to favor protection over destruction.
2Productivity
If hNE is released from neutrophil granules into the extracellular space, then its physiological function of degrading foreign organic molecules is performed, but its uncontrolled activity leads to degradation of extracellular matrix and plasma proteins
Solution Approach 1:
The patent converts the harmful uncontrolled proteolytic activity of hNE into a beneficial controlled inhibition. The 2-pyridone derivatives bind reversibly to the active site of hNE, transforming the enzyme from a destructive force into an inhibited complex. This reversible inhibition allows the system to maintain proteolytic capacity when needed while preventing tissue destruction when uncontrolled activity would occur.
Solution Approach 2:
The patent employs small-molecule inhibitors that are pharmacologically active at low concentrations and can be rapidly cleared from the system. The 2-pyridone derivatives act as transient, high-efficacy inhibitors that provide rapid protection against hNE-mediated tissue destruction without requiring long-lasting or complex therapeutic agents. Their short half-life and high specificity allow for rapid on/off control of enzyme activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2-pyridone derivatives effectively inhibit human neutrophil elastase, potentially reducing tissue damage and alleviating symptoms in conditions like pulmonary emphysema, COPD, and other inflammatory diseases by restoring the protease-antiprotease balance.
Implementation Method 1
Human neutrophil elastase (hNE) is a destructive enzyme implicated in various inflammatory diseases due to its uncontrolled proteolytic activity
Implementation Method 2
Elastases are possibly the most destructive enzymes in the body, having the ability to degrade virtually all connective tissue components
Data Source
AI summary
There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.